Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: A case-matched cohort study in east China

Diseases of the Esophagus

Volumn 21, Issue 3, 2008, Pages 207-213

  Zhang, Jia ^a   Zhang, Y W ^a   Chen, Z W ^a   Zhou, X Y ^a   Lu, S ^b   Luo, Q Q ^b   Hu, H ^a   Miao, L S ^a   Ma, L F ^a   Xiang, J Q ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Esophageal cancer; Molecular marker

Indexed keywords

CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; MYC PROTEIN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CELIAC LYMPH NODE METASTASIS; CERVICAL LYMPH NODE METASTASIS; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHINA; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED;

EID: 42649126390     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00748.x     Document Type: Article

References (30)

1. Liu J F, Wang Q Z, Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei. China Br J Surg 2004; 91: 90-8.
2. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-33.
3. Kaklamanos I G, Walker G R, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754-61.
4. Kelsen D P, Ginsberg R, Pajak T F et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
5. Iyer R, Wilkinson N, Demmy T et al. Controversies in the multimodality management of locally advanced esophageal cancer: Evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 2004; 11: 641-3.
6. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004; 53: 925-30.
7. Chong G, Cunningham D. The role of preoperative chemotherapy for esophageal cancer: When is surgery alone feasible? Nat Clin Pract Oncol 2005; 2: 172-3.
8. McCabe M L, Dlamini Z. The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 2005; 5: 1113-30.
9. Sarbia M, Stahl M, Fink U et al. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991-7.
10. Miyazaki T, Kato H, Faried A et al. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 2005; 25: 2749-55.
11. Gibson M K, Abraham S C, Wu T T et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-8.
12. Zhang J, Shen K W, Liu G et al. Antigen profiles of disseminated tumor cells and microenviromental characteristics in bone marrow of breast cancer. European J Surg Oncol 2003; 29: 121-6.
13. Fu X L, Zhu X Z, Shi D R et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23: 143-52.
14. Malthaner R A, Wong R K, Rumble R B et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2004; 2: 35.
15. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114: 205-9.
16. Minsky B D. Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma. Cancer Treat Rev 1995; 21: 407-14.
17. Liu H C, Hung S K, Huang C J et al. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11: 5367-72.
18. Ando N, Iizuka T, Ide H et al. Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 2003; 21: 4592-6.
19. Lee J, Lee K E, Im Y H et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2005; 80: 1170-5.
20. Shiozaki A, Yamagishi H, Itoi H et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Report 2005; 13: 667-72.
21. Armanios M, Xu R, Forastiere A A et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: Phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22: 4495-9.
22. Brenner B, Ilson D H, Minsky B D et al. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004; 22: 45-52.
23. Mauer A M, Kraut E H, Krauss S A et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005; 16: 1320-5.
24. Albertsson M, Kadar L, Bergenfeldt M. Experiences with the use of oxaliplatin in esophageal carcinoma. Acta Oncol 2006; 45: 103-5.
25. Sumpter K, Harper-Wynne C, Cunningham D et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-83.
26. Metzger R, Schneider P M, Warnecke-Eberz U et al. Molecular biology of esophageal cancer. Onkologie 2004; 27: 200-6.
27. Sunada F, Itabashi M, Ohkura H et al. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. Gastroenterol 2005; 11: 5696-700.
28. Itaya M, Yoshimoto J, Kojima K et al. Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity. Meth Mol Med 2005; 110: 213-27.
29. Hsia J Y, Chen C Y, Hsu C P et al. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma 2001; 48: 483-8.
30. Takayama T, Nagao M, Sawada H et al. Bcl-X expression in esophageal squamous cell carcinoma: Association with tumor progression and prognosis. J Surg Oncol 2001; 78: 116-23.